MPR spoke with Dr Daniela Carvalho, an investigator in the CHORD trial, the results form which formed the basis for the approval of Otarmeni.

The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and adult patients with OTOF-related sensorineural hearing loss.

Hearing recovery occurred in 90 percent of gene therapy patients with OTOF-related hearing loss, with particular improvements in children.

The US FDA has approved Otarmeni, a groundbreaking gene therapy by Regeneron, to restore natural hearing in children born ...

American drugmaker Regeneron's Otarmeni can restore natural hearing in children born deaf due to a genetic mutation ...

When the parents of a toddler born profoundly deaf learned their child carried mutations in both copies of the OTOF gene, a ...

The FDA approved lunsotogene parvec-cwha as the first gene therapy for genetic hearing loss caused by biallelic OTOF variants ...

Envoy Medical Inc, a hearing health company pioneering fully implanted hearing solutions, announced that all 56 patients implanted and enrolled in its pivotal clinical trial evaluating the fully ...

The kinocilium of vestibular hair cells is a unique organelle with molecular features of primary and motile cilia and may serve as an active, force-generating element within the hair bundle.

The FDA granted accelerated approval to lunsotogene parvec (Otarmeni) as the first gene therapy for genetic hearing loss, the ...

The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...

The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...